Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Perinatol ; 37(7): 818-821, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28406487

RESUMEN

OBJECTIVE: There is a paucity of studies on the impact of maternal body mass index (BMI) on macronutrient content of human milk colostrum (HMC). The objective of this study was to compare macronutrient content of HMC in healthy women of term infants in relation to their BMI. We hypothesized that mother habitus influences human milk colostrum content. METHOD: Colostrum was collected from 109 healthy mothers of hospitalized healthy term infants divided into four prepregnancy BMI groups: 12 underweight, 59 normal weight, 20 overweight, and 18 obese women between 24 and 72 h after birth. Macronutrient content was measured using mid-infrared spectroscopy. RESULTS: There were no significant differences in macronutrients between the BMI groups. We performed four separate stepwise backward multiple regression analyses taking into account fat, carbohydrate, protein or energy content as dependent variables and maternal BMI, parity, gestational age, infant gender, maternal age, maternal education, mode of delivery and time postdelivery. In these analyses, fat, carbohydrate and energy content were not related to maternal BMI, while protein content was significantly and positively correlated with BMI (P=0.008) and negatively correlated with gestational age (P=0.004) and time postdelivery (P<0.001). Colostrum carbohydrate content was positively correlated with parity. Colostrum fat and energy content were negatively correlated with maternal age and positively correlated with parity. CONCLUSION: Most macronutrient and energy content of colostrum are unaffected by prepregnancy maternal BMI, with the exception of protein content that is positively related to maternal BMI.


Asunto(s)
Índice de Masa Corporal , Carbohidratos/análisis , Calostro/química , Paridad , Adulto , Escolaridad , Femenino , Edad Gestacional , Voluntarios Sanos , Humanos , Recién Nacido , Israel , Masculino , Edad Materna , Proteínas de la Leche/análisis , Embarazo , Análisis de Regresión , Nacimiento a Término , Adulto Joven
2.
Anticancer Res ; 31(5): 1769-75, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21617238

RESUMEN

BACKGROUND: Possible predictive markers of response to neoadjuvant radiochemotherapy (NRCT) of esophageal cancer have been identified. PATIENTS AND METHODS: Patient biopsies were obtained from both tumor and normal tissue before the NRCT of locally advanced esophageal squamous cell carcinoma. Protein solutions were separated and immunoblot analysis was performed with heat shock protein (Hsp)16.2, heme-binding protein 2 (SOUL), BCL2-associated X protein (Bax), B-cell-associated leukemia protein 2 (Bcl-2) and heat shock protein 90 (Hsp90) antibodies. Following NRCT, the patients were restaged according to the Response Evaluation Criteria In Solid Tumors (RECIST). Following resections the pathological down-staging was evaluated. RESULTS: Clinical restaging revealed a response rate of 65%. Pathological examination revealed down-staging in 30% and 25% of the cases for the T and N categories respectively. Compared to the normal esophageal mucosa, a decreased expression of Hsp16.2, Hsp90 and SOUL proteins and an increased Bax/Bcl-2 ratio was found in the responding tumors. CONCLUSION: Hsp16,2, Hsp90 and SOUL expression and Bax/ Bcl-2 ratio correlates to the efficacy of NRCT and predict outcome in patients with locally advanced squamous-cell esophageal cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/terapia , Neoplasias Esofágicas/terapia , Terapia Neoadyuvante , Proteínas de Neoplasias/metabolismo , Adulto , Anciano , Western Blotting , Carcinoma de Células Escamosas/metabolismo , Estudios de Casos y Controles , Quimioterapia Adyuvante , Cisplatino/administración & dosificación , Terapia Combinada , Neoplasias Esofágicas/metabolismo , Esófago/efectos de los fármacos , Esófago/metabolismo , Esófago/efectos de la radiación , Femenino , Fluorouracilo/administración & dosificación , Proteínas HSP90 de Choque Térmico/metabolismo , Proteínas de Choque Térmico Pequeñas/metabolismo , Proteínas de Unión al Hemo , Hemoproteínas/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intracelular , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Proteínas Gestacionales/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Radioterapia Adyuvante , Tasa de Supervivencia , Resultado del Tratamiento , Proteína X Asociada a bcl-2/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA